130 likes | 141 Views
Explore the morbidity and mortality patterns, as well as the usage of anti-asthmatic drugs in Croatia from 2006 to 2015. The study encompasses data from various health reports and aims to provide insights for healthcare professionals and policymakers.
E N D
Morbidity, mortality and utilisation of drugs for chronic obstructive airway diseases Birgitta Maćešić, Mirica Rapić
Introduction • Chronic obstructive airway diseases (asthma and COPD) • COPD – prevalence 4% - 10% (increasing) • COPD - the fifth cause of death (WHO) • COPD – low quality of life • COPD - absenteism and invalidity
Aims and purpose To investigate morbidity and mortality trends and utilisation of anti-asthmatics in Croatia, 2006 - 2015 The obtained results might be useful in raising the awareness if anti-asthmatics drug’s utilisation is in accordance to evidence based knowledge and to forecast a future trends important for family doctors and decision makers
Method • Primary Health Care (PHC) morbidity data – Croatian Health-service Yearbooks, 2006 – 2015 • ICD-X – respiratory - J diagnostic codes • J40 - J47 codes (asthma and COPD) – one group • Mortality data – Annual Reports of Croatian Institute for Public Health • Specific mortality – obstructive pulmonary diseases
Anti-asthmatic drugs utilisation data • Annual Reports of Croatian Agency for Medicinal Products and Medical Devices, 2006 - 2015 • Anatomic-therapeutic clasification (ATC) index • Defenied daly doses/1000/day (DDD/TID)
Anti-asthmatics • Respiratory – R, R03 – antiasthamtics • R03AC - Saba, Laba, • R03BA – glukocorticoids, • R03BB - anticholinergics (Sama, Lama), • R03AK - adrenergics + corticosteroids, • R03AL - adrenergics i anticholinergics, • R03DA - xanthines, • R03DC - Leukotriene receptor antagonists, R03DX - Other - omalizumab, roflumilast
Results • Morbidity • Drug utilisation • Mortality
Morbidity of chronic obstructive airway diseases (J40 – J47)
Conclusions • Decreased morbidity trend • Increased drug utilisation • Higher increase in the groups of: anticholinergics (R03BB) by 4,14 times; glucocorticoids (R03BA) by 2,24 times; Leukotriene receptor antagonists ( R03DC) by 1,56 times • Increased mortality trend
For communication • Birgitta Maćešić, bacc. med. techn., Specijalistička ordinacija obiteljske medicine “Dr. Mirica Rapić”, Karlovac • Mirica Rapić, specialist of Family Medicine, Specijalisitčka ordinacija obiteljske medicine “Dr. Mirica Rapić”, Karlovac • e-mail: mirica.rapic@ka.t-com.hr